Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

Yang, Chih-Hsin, Yu, Chong-Jen, Shih, Jin-Yuan, Chang, Yeun-Chung, Hu, Fu-Chang, Tsai, Meng-Chin, Chen, Kuan-Yu, Lin, Zhong-Zhe, Huang, Ching-Ju, Shun, Chia-Tung, Huang, Chin-Lun, Bean, James, Cheng, Ann-Lii, Pao, William, Yang, Pan-Chyr · 2008 · Journal of Clinical Oncology

Abstract

Purpose: To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients and Methods: We designed a phase II study to test gefitinib antitumor efficacy in advanced-stage, chemotherapy-naive NSCLC patients. Patients were treated with gefitinib 250 mg/d. Tumor assessments were performed every 2 months. Responding or stable patients were treated until progression or unacceptable toxicity. All scans were reviewed independently. EGFR exons 18-21 sequence, K-ras exon 2 sequence, and MET gene copy numbers were examined in available samples. Clinical or molecular predictors of TTF were examined by multivariate analysis. Results: One hundred six patients were enrolled. Ninety patients had tumor samples for biomarker tests. Overall response rate was 50.9% (95% CI, 41.4% to 60.4%). Median TTF was 5.5 months, and median overall survival (OS) was 22.4 months. The response rate and median TTF of the patients with exon 19 deletion (n = 20) were 95.0% and 8.9 months, for exon 21 L858R mutation (n = 23) were 73.9% and 9.1 month, and for other types of EGFR mutations (N = 12) were 16.7% and 2.3 months, respectively. In multivariate analysis, the presence of EGFR deletion exon 19 or L858R EGFR mutations in adenocarcinoma patients predicted longer TTF. High copy number of MET seemed to correlate with shorter TTF in patients with gefitinib-sensitive activating EGFR mutations. Conclusion: In this prospective study, EGFR exon 19 deletion or L858R mutations in adenocarcinoma were the best predictors for longer TTF in stage IIIB/IV chemotherapy-naive NSCLC patients receiving first-line gefitinib monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.6695

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 32

  1. 10.1016/S1556-0864(15)30415-9 · DOI · Paper page
  2. 10.1200/JCO.2003.10.038 · DOI · Paper page
  3. 10.1200/JCO.2006.06.3958 · DOI · Paper page
  4. 10.1056/NEJMoa050736 · DOI · Paper page
  5. 10.1002/cncr.22220 · DOI
  6. 10.1158/1078-0432.CCR-04-2149 · DOI
  7. Lange T, Muller-Tidow C, Serve H, et al: First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep 14:1539,2005-1542, · doi:10.3892/or.14.6.1539
  8. 10.1038/sj.bjc.6603393 · DOI · Paper page
  9. 10.1200/JCO.2005.02.5825 · DOI · Paper page
  10. 10.1038/sj.bjc.6603159 · DOI
  11. 10.1016/S1556-0864(15)31577-X · DOI
  12. 10.1016/j.lungcan.2006.07.013 · DOI
  13. 10.1073/pnas.0405220101 · DOI · Paper page
  14. 10.1200/JCO.2005.01.388 · DOI · Paper page
  15. 10.1200/JCO.2005.09.985 · DOI · Paper page
  16. 10.1200/JCO.2005.00.992 · DOI · Paper page
  17. 10.1002/ijc.21458 · DOI · Paper page
  18. 10.1158/0008-5472.CAN-06-1951 · DOI · Paper page
  19. 10.1371/journal.pmed.0020017 · DOI · Paper page
  20. Yang CH, Yu CJ, Chen KY, et al: A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non–small-cell lung cancer in East Asian patients. J Clin Oncol 24:405s,2006, (suppl; abstr 7167) · doi:10.1200/jco.2006.24.18_suppl.7167
  21. 10.1016/S1556-0864(15)30013-7 · DOI · Paper page
  22. 10.1016/j.lungcan.2007.01.025 · DOI
  23. 10.1200/JCO.2005.05.4692 · DOI · Paper page
  24. 10.1200/JCO.2006.07.3585 · DOI · Paper page
  25. 10.1016/S0012-3692(15)52173-9 · DOI
  26. 10.1002/jcb.10239 · doi:10.1002/jcb.10239
  27. 10.1093/jnci/dji112 · DOI · Paper page
  28. 10.1002/cncr.22593 · DOI
  29. 10.1200/JCO.2005.02.7078 · DOI · Paper page
  30. 10.1200/JCO.2005.02.857 · DOI · Paper page
  31. 10.1016/j.lungcan.2007.06.024 · DOI
  32. 10.1158/1078-0432.CCR-05-2324 · DOI · Paper page

Cited by

See all 235

Metadata

Authors
Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., Huang, C.-L., Bean, J., Cheng, A.-L., Pao, W., & Yang, P.-C.
Venue
Journal of Clinical Oncology
Published
2008-06-01
Volume
26
Issue
16
Pages
2745-2753
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2130254323
Cited by
235
References
9
FWCI
25.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. https://app.cochat.ai/papers/10.1200/jco.2007.15.6695
The paper
Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., Huang, C.-L., Bean, J., Cheng, A.-L., Pao, W., & Yang, P.-C. (2008). Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.6695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.